Ahh yes, my bad, I remember that conversation now. I think our original intent for this suggestion was to reduce the amount of clozes on c1 so would prefer adding it back as c2 as @Ahmed7 suggested
I can’t find this in the maintainer handbook but I think this is a convo we’ve had in Slack a while ago or with Jacob, not sure which one specifically
1 Like
I shortened the extra section as per @Cameron request. I removed the hydralazine/nitrate point and also deleted the mention of GLP-1 agonists, as I didn’t find strong evidence supporting their use in HFrEF. Most trials and meta-analyses haven’t shown a clear benefit in this context. However, we could consider including it in a card focused on ASCVD in diabetes rather than in one about HF, as it seems far from being a tested topic in HF management
The image below is from a new bulk suggestion (i.e., another open suggestion for this card)
2 Likes
I think if we keep it all on this card then we should delete nid:1522787422448
I like it! I think the bit about GLP-1s was @herstein.jacob 's suggestion originally from Slack IIRC. The decreased CV risk is a thing with high-dose semaglutide (as I hear every day in WeGovy commercials-- ‘I’m losing the weight, I’m keeping it off, and I’m lowering my CV risk!’). But I also never saw it tested when I was doing UWorld. Probably it’ll be added at some point but I think it’s probably overkill at this point
1 Like
specifically it’s the guy in the commercial who’s repairing the car with his grandson. he’s the one concerned about his cv risk and wants to lower it with a glp-1 agonist. in case you were wondering
2 Likes
It does decrease the CV risk in patients with diabetes (who are at increased risk of ASCVDs), but this is not proven to be helpful for HF patients (which the card is testing)
Below is what UTD says about this, it was mentioned once in UW along with SGLT-2 inhibitors as agents that decrease ASCVD in patients with T2DM but didn’t mention anything about HF
